Clinical Trial Update: Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating adjuvant pembrolizumab versus observation after curative resection in patients with stage I non-small cell lung cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Greg Durm, MD | Conditions: NSCLC, Stage I | Phase 2 | Status: RECRUITING